Tandem Diabetes Care Faces Securities Laws Investigation Over Insulin Pump Malfunction

The national shareholder rights litigation firm has launched an investigation into claims that Tandem Diabetes Care, Inc. issued false or misleading statements and/or failed to disclose crucial information to investors. The company recently admitted that certain insulin pumps had a malfunction that could lead to hyperglycemia and require hospitalization. As a result, shares of Tandem dropped significantly over several trading sessions. If you're a shareholder who suffered losses, you may be entitled to compensation. The Schall Law Firm is offering free consultations to discuss your rights and potential next steps.

Key Takeaways:

• The Schall Law Firm is investigating claims on behalf of Tandem Diabetes Care investors for securities law violations.
• The investigation focuses on the company's alleged failure to disclose information about its insulin pumps' malfunctions.
• Tandem Diabetes Care admitted to the malfunction on August 7, 2025, stating it could lead to hyperglycemia and hospitalization.
• Shares of Tandem dropped over several trading sessions following the disclosure.
• The Schall Law Firm is offering free consultations to discuss potential claims and next steps for affected investors.
• Brian Schall of the Schall Law Firm can be reached through the firm's website or by email to discuss investor rights.
• The firm specializes in securities class action lawsuits and shareholder rights litigation.

Statistics:

• August 7, 2025: Tandem Diabetes Care announced the malfunction of its insulin pumps.
• Late July 2025: The company sent notices to impacted customers about the malfunction.
• Over several trading sessions: Shares of Tandem dropped significantly.
• NASDAQ: Tandem Diabetes Care shares are listed under the ticker symbol .

Sources:

• The Schall Law Firm
• Brian Schall, Esq.
• info@schallfirm.com
• View original press release to download multimedia (PRNewswire, 2025)